The concern of generic competition has consistently loomed around copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the future of connected drug investments. While early periods saw impressive profits, the patent lapse has allowed the way for less expensive copies, possibly reducing earnings and posing a genuine hazard for